Patient-specific tumor neoantigen–HLA complex (NeoAg-HLA complex)

Patient-specific tumor neoantigen–HLA complexes are unique molecular targets formed when mutated proteins (neoantigens) within a tumor are processed into peptides and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules. These complexes are central to the immune system's ability to distinguish malignant cells from healthy tissue, as neoantigens arise from somatic mutations and are not typically subject to central T-cell tolerance. In the context of oncology, these complexes serve as the primary targets for personalized immunotherapies, including neoantigen vaccines and adoptive T-cell therapies. By priming or engineering T cells to recognize these specific peptide-HLA combinations, clinicians can induce a highly targeted anti-tumor immune response. The identification of these complexes often requires advanced next-generation sequencing and bioinformatics to predict which mutations will result in immunogenic epitopes. However, the effectiveness of such therapies can be limited by tumor heterogeneity and mechanisms of immune escape, such as the loss of HLA expression or the development of an immunosuppressive microenvironment.

Other names

Tumor-specific neoantigen-MHC complexPersonalized neoantigen-HLA complexNeoepitope-HLA complexpMHC complexTSA-HLA complexNeoantigen-MHC class I complexNeoantigen-MHC class II complex

Induction of a specific cytotoxic T-cell response against tumor cells by presenting unique, mutation-derived peptides in the context of the patient's own HLA molecules, thereby bypassing central tolerance and enabling targeted cell lysis.